Tenofovir did not increase the incidence nephrotoxicity in limited numbers of HIV-positive patients using chemotherapy or HCV-coinfeced patients using ribavirin

HIV Treat Bull - Vol. 7, No. 7/8, September 2006

Two posters from the Chelsea and Westminster used their database of over 5,000 patients to look prospectively at patients using tenofovir in their ARV combination, who were also using potentially nephroptoxic chemotherapy for haematological malignancies, or retrospectively at HCV coinfected patients using ribavirin for HCV treatment.

Tenofovir was included in the regimen for 50/142 patients (35%) treated with anthracycline-based combination chemotherapy and concomitant HAART. [1]

At the start of chemotherapy, 8 (6%) had CTC grade 1-4 renal toxicity (elevated serum creatinine (Cr) >110 umol/L), including one patient on chronic haemodialysis. These included 3 patients on TDF and 5 not on TDF (p=0.93). The median peak serum Cr for these patients was 152 umol/lL(range 137-234), and did not differ between TDF group and non TDF group (p=0.48) During the course of chemotherapy, a further 9 patients developed renal impairment; 2/50 on TDF and 7/92 not on TDF (p=0.38). The median peak serum Cr in this group was 274umol/L (range 166-581), this was lower in the TDF group (median 176 umol/L, range 166-187) than the non-TDF group (median 277 umol/L, range 207-581) (Mann Whitney U p=0.04).

In the second analysis, 350 HIV/HCV coinfected patients with at least two recorded creatinine values of >120 umol/L were identified, of which had been exposed to tenofovir and/or ribavirin, and and creatine clearance was compared by treatment use. [2]

The prevalence of abnormal creatinine was 32.1 per 1000 patients (95% CI: 10.4 to 73.2) and 19.2 per 1000 patients (95% CI: 4.0-55.1) in patient exposed to either tenofovir or ribavirin respectively, and 12.8 per 1000 patients (95% CI: 1.5-45.6) in patients using both drugs,

Although these analysis do not comment on channelling bias (for example, treatment choice may have been affected in patients with any pre-existing renal concerns), it is important that no signal of increased toxicity were reported.

References

1. Jones R, Low E, Nelson M et al. Tenofovir does not increase the incidence of chemotherapy related nephrotoxicity. Poster abstract TUPE0047.
2. Jones R, Bower M, Mandalia S et al. Renal toxicity in HIV/Hepatitis C co-infected individuals exposed to tenofovir and/or ribavarin. Poaster abstract CDB0734.

2006-09-10
IB060709-22

©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.